Overview A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Status: Recruiting Trial end date: 2021-12-01 Target enrollment: Participant gender: Summary This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria. Phase: Phase 1 Details Lead Sponsor: Celldex Therapeutics